重组人源化抗PD-L1单克隆抗体注射液用于晚期实体瘤患者的安全性、耐受性、药代动力学和药效学临床研究
[Translation] Clinical study on the safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant humanized anti-PD-L1 monoclonal antibody injection in patients with advanced solid tumors
评估重组人源化抗PD-L1单克隆抗体(JS003)在经治的晚期或复发性实体瘤受试者中的安全性、耐受性和剂量限制性毒性(DLT)。
[Translation] To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of a recombinant humanized anti-PD-L1 monoclonal antibody (JS003) in subjects with previously treated advanced or recurrent solid tumors.
100 Clinical Results associated with Suzhou Junshi Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Suzhou Junshi Biomedical Technology Co., Ltd.
100 Deals associated with Suzhou Junshi Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Suzhou Junshi Biomedical Technology Co., Ltd.